Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has reached the enrollment mid-point in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009. Fiscal 2009 Summary -------------------...

- Fourth quarter and year end financial results to be released February 17, 2010 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced a final judgment (the "Cipher Judgment") has been entered in favour of Cipher in relation to pending patent litigation with Purdue Pharma...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2009. Q3 2009 Summary --------------- - Total revenue...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Dr. William Claypool, M.D., has been appointed to its Board of Directors. Since October 2008, Dr. Claypool has been a Senior Partner at...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or the "Company") today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the...

- Third quarter financial results to be released November 4, 2009 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 26 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of...